Biomea fusion, inc. reports inducement grants under nasdaq listing rule 5635(c)(4)

Redwood city, calif., april 01, 2025 (globe newswire) -- biomea fusion, inc. (“biomea” or the “company”) (nasdaq: bmea), a clinical-stage diabetes and obesity medicines company, today announced that on march 23, 2025, the compensation committee of biomea's board of directors granted two new employees non-qualified stock options to purchase an aggregate of 30,000 shares of the company's common stock. the shares underlying each employee's stock options will vest 1/16 on a quarterly basis over four years, in each case subject to each such employee's continued employment with the company on such vesting dates. all of the above-described awards were made under biomea's 2023 inducement equity plan (the “plan”).
NDAQ Ratings Summary
NDAQ Quant Ranking